Across the recent three months, 15 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:APLS), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 8 | 4 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.47, a high estimate of $100.00, and a low estimate of $41.00. This current average has decreased by 3.52% from the previous average price target of $81.33.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of Apellis Pharmaceuticals’s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anupam Rama | JP Morgan | Lowers | Overweight | $57.00 | $64.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $64.00 | $72.00 |
| Eliana Merle | UBS | Lowers | Buy | $83.00 | $85.00 |
| Laura Chico | Wedbush | Raises | Neutral | $41.00 | $38.00 |
| Salveen Richter | Goldman Sachs | Raises | Buy | $74.00 | $66.00 |
| Colleen Kusy | Baird | Raises | Outperform | $96.00 | $86.00 |
| Joseph Stringer | Needham | Maintains | Buy | $85.00 | $85.00 |
| Douglas Tsao | HC Wainwright & Co. | Lowers | Buy | $83.00 | $92.00 |
| Salveen Richter | Goldman Sachs | Lowers | Buy | $66.00 | $77.00 |
| Joseph Stringer | Needham | Maintains | Buy | $85.00 | $85.00 |
| Akash Tewari | Jefferies | Maintains | Buy | $80.00 | $80.00 |
| Colleen Kusy | Baird | Lowers | Outperform | $86.00 | $100.00 |
| Colleen Kusy | Baird | Maintains | Outperform | $100.00 | $100.00 |
| Salveen Richter | Goldman Sachs | Lowers | Buy | $77.00 | $90.00 |
| Colleen Kusy | Baird | Maintains | Outperform | $100.00 | $100.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from ‘Outperform’ to ‘Underperform’. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock’s future value. Comparing the current and prior price targets provides insight into how analysts’ expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock’s potential future performance.
For valuable insights into Apellis Pharmaceuticals’s market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Apellis Pharmaceuticals analyst ratings.
Unveiling the Story Behind Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Financial Milestones: Apellis Pharmaceuticals’s Journey
Market Capitalization Analysis: Below industry benchmarks, the company’s market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Apellis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 110.26% as of 30 June, 2024. This reflects a substantial increase in the company’s top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals’s net margin is impressive, surpassing industry averages. With a net margin of -18.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals’s ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Apellis Pharmaceuticals’s ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.34%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Apellis Pharmaceuticals’s debt-to-equity ratio surpasses industry norms, standing at 1.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
